@article{102478,
  keywords = {Ivermectin, Covid-19, Anti-helminthic, Gynecologic cancers},
  author = {Mujumdar V and Huang M and Smith LC and Musa F},
  title = {Ivermectin and gynecologic cancer: What’s the data?},
  abstract = {<h2>Highlights</h2>

<p>•</p>

<p>Ivermectin is currently approved by the US Food and Drug Administration (FDA) in 1996 as an oral medication for intestinal strongyloidiasis and onchocerciasis.</p>

<p>•</p>

<p>The data on ivermectin as a gynecologic cancer-fighting compound is lacking.</p>

<p>•</p>

<p>Clinical studies on ivermectin use in cancer are limited to effects observed in cell lines.</p>

<p>•</p>

<p>We have not assessed ivermectin’s safety and efficacy in gynecologic cancers.</p>

<p>•</p>

<p>We do not recommend and strongly caution the use of ivermectin in the treatment of gynecologic cancers.</p>
},
  year = {2025},
  journal = {Gynecologic Oncology Reports},
  volume = {60},
  pages = {101803},
  publisher = {Elsevier BV},
  issn = {2352-5789},
  url = {https://pdf.sciencedirectassets.com/311234/1-s2.0-S2352578925X00047/1-s2.0-S2352578925001286/main.pdf?X-Amz-Security-Token=IQoJb3JpZ2luX2VjEOj%2F%2F%2F%2F%2F%2F%2F%2F%2F%2FwEaCXVzLWVhc3QtMSJGMEQCIG9G%2B0YitC30FMja3b%2Bij0Zvho9WKM4tnKjTOIcSC1whAiBNYP7b14uy},
  doi = {10.1016/j.gore.2025.101803},
  language = {eng},
}